Lavipharm Statistics

Total Valuation

Lavipharm has a market cap or net worth of EUR 124.33 million. The enterprise value is 146.97 million.

Market Cap	124.33M
Enterprise Value	146.97M

Important Dates

The next estimated earnings date is Monday, March 24, 2025.

Earnings Date	Mar 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Lavipharm has 168.69 million shares outstanding. The number of shares has increased by 73.56% in one year.

Current Share Class	n/a
Shares Outstanding	168.69M
Shares Change (YoY)	+73.56%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.51%
Owned by Institutions (%)	3.49%
Float	64.01M

Valuation Ratios

The trailing PE ratio is 17.42.

PE Ratio	17.42
Forward PE	n/a
PS Ratio	2.41
PB Ratio	2.42
P/TBV Ratio	17.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.80, with an EV/FCF ratio of -37.16.

EV / Earnings	19.87
EV / Sales	2.86
EV / EBITDA	18.80
EV / EBIT	41.10
EV / FCF	-37.16

Financial Position

The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.61.

Current Ratio	1.24
Quick Ratio	0.62
Debt / Equity	0.61
Debt / EBITDA	4.01
Debt / FCF	-7.92
Interest Coverage	1.63

Financial Efficiency

Return on equity (ROE) is 15.20% and return on invested capital (ROIC) is 2.78%.

Return on Equity (ROE)	15.20%
Return on Assets (ROA)	1.85%
Return on Capital (ROIC)	2.78%
Revenue Per Employee	171,147
Profits Per Employee	24,653
Employee Count	307
Asset Turnover	0.43
Inventory Turnover	1.60

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.99% in the last 52 weeks. The beta is 0.88, so Lavipharm's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	-10.99%
50-Day Moving Average	0.75
200-Day Moving Average	0.84
Relative Strength Index (RSI)	46.56
Average Volume (20 Days)	65,599

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Lavipharm had revenue of EUR 51.34 million and earned 7.40 million in profits. Earnings per share was 0.04.

Revenue	51.34M
Gross Profit	23.25M
Operating Income	3.58M
Pretax Income	2.76M
Net Income	7.40M
EBITDA	7.11M
EBIT	3.58M
Earnings Per Share (EPS)	0.04

Full Income Statement

Balance Sheet

The company has 8.69 million in cash and 31.31 million in debt, giving a net cash position of -22.62 million or -0.13 per share.

Cash & Cash Equivalents	8.69M
Total Debt	31.31M
Net Cash	-22.62M
Net Cash Per Share	-0.13
Equity (Book Value)	51.18M
Book Value Per Share	0.30
Working Capital	9.20M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.35 million and capital expenditures -6.30 million, giving a free cash flow of -3.96 million.

Operating Cash Flow	2.35M
Capital Expenditures	-6.30M
Free Cash Flow	-3.96M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross margin is 45.27%, with operating and profit margins of 6.96% and 14.40%.

Gross Margin	45.27%
Operating Margin	6.96%
Pretax Margin	5.38%
Profit Margin	14.40%
EBITDA Margin	13.84%
EBIT Margin	6.96%
FCF Margin	n/a

Dividends & Yields

Lavipharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-73.56%
Shareholder Yield	-73.56%
Earnings Yield	5.96%
FCF Yield	-3.18%

Stock Splits

The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.

Last Split Date	Aug 1, 2022
Split Type	Reverse
Split Ratio	0.3333333333

Scores

Lavipharm has an Altman Z-Score of 1.41. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.41
Piotroski F-Score	n/a